Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Proceedings of the 8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)

Oral presentation

Clinically isolated syndrome in collagen diseases; approaches and treatments

Kazumasa Yokoyama* and Nobutaka Hattori

  • * Corresponding author: Kazumasa Yokoyama

Author affiliations

Department of Neurology, Juntendo University School of Medicine, Hongo, Tokyo, 113-8421, Japan

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2012, 14(Suppl 1):O4  doi:10.1186/ar3559


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/14/S1/O4


Published:9 February 2012

© 2012 Yokoyama and Hattori; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Acute isolated neurological syndromes, such as optic neuropathy or transverse myelopathy, may cause diagnostic problems since they can be the first presentations in a number of demyelinating disorders including multiple sclerosis (MS) and collagen diseases. However, clinical presentation and lesions evidenced by magnetic resonance imaging may be similar. Collagen disease coexists in demyelinating disorders and frequently various collagen disease related autoantibodies are positive in daily practice.

Hence, the algorithm to overcome these diagnostic and therapeutic issues should be clarified.

B cell immunity in demyelinating disorders

In primary demyelinating disease, MS, a renewed interest in the role of humoral immunity in the pathophysiology has been investigated because oligoclonalIgG band in the CSF and increased intrathecalIgG synthesis are used as an auxiliary diagnosis measure. Moreover, in the secondary progressive MS, meningeal B-cell follicles are associated with early onset of the disease and severe cortical pathology. B cell but not plasma cell depletion therapy with single treatment by Rituximab in MS showed reduced inflammatory brain lesions and clinical relapses.

Oligodendropathy and astrocytopathy in demyelinating disorders

Neuromyelitisoptica (NMO) was previously considered to be a variant of MS but is now recognized as an astrocytopathy and secondary demyelinating event mimicking MS characteristics occurring due to autoantibody mediated mechanisms. Advancement of molecular biology makes it possible to differentiate MS by measuring abnormal autoantibody to aquaporin 4 (water channel). Interestingly, collagen diseases coexist more frequently with NMO than with MS. B cell depletion therapy with Rituximab has showed the same benefits, although, plasma exchange therapy is more effective with NMO than with MS.

TNF therapy and demyelinating event

A report indicates that adverse events such as the demyelinating lesion in the brain, optic neuritis, and neuropathy occurred after treatment with anti-TNF alpha therapy in collagen disease, and TNF antagonizing therapy showed worsening in a clinical trial with MS. Pathogenesis of these events such as primary or secondary demyelination are still in enigma.

In this presentation, I will decode the temporal and spatial demyelinating processes in collagen diseases and show practical approaches and treatments.

References

  1. Franciotta D, Salvetti M: B cells and multiple sclerosis.

    Lancet Neurol 2008, 7:852-8. PubMed Abstract | Publisher Full Text OpenURL

  2. Bernatsky S, Renoux C: Demyelinating events in rheumatoid arthritis after drug exposures.

    Ann Rheum Dis 2010, 69:1691-3. PubMed Abstract | Publisher Full Text OpenURL